Dr. Nader Al Dewik (Qatar-HMC/ HBKU)
Dr. Al-Dewik is a Director of Translational and Precision Medicine Research, Principal Investigator at Hamad Medical Corporation (HMC), and A/Professor in Human Genetics, Genomic, and Precision Medicine Program, College of Health and Life Sciences, Hamad Bin Khalifa University (HBKU) in the State of Qatar.
As a critical principal investigator, Dr. Al-Dewik has successfully gained several research grants funded by different funding bodies and secured up to USD$ 8 M between 2008 - 2022 through collaboration with several international teams on translational molecular genetics and precision medicine projects. His primary research interests address high-priority maternal and neonatal health, such as inherited genetic disorders, congenital anomalies, and preterm babies.
He was also awarded an innovation fund from Qatar Science and Technology Park (QSTP) to develop a molecular kit. Dr. Al-Dewik's approach is multidisciplinary and collaborative.
Dr. Al-Dewik has presented original research findings at several local, regional, and international conferences and published them in peer-reviewed journals. He has published over 50 articles in peer-reviewed journals, book chapters, and abstracts. He is acting as a reviewer for many cancer and genetics journals.
Dr. Al-Dewik is also a reviewer of research grant proposals such as The Research Council (TRC) of the Sultanate of Oman and Qatar University Internal Grants.
Dr. Al-Dewik is a managing editor of Frontiers in Bioscience special issues along with Ad Hoc reviewer for the Molecular Cancer, BMC, Springer Nature, Journal of Translational Medicine, BMC, Springer nature, the Epigenetics Taylor & Francis, Journal of Pediatric Genetics, Metagene Elsevier Journal, the Journal of Cancer Therapy (JCT), Biomarkers in Cancer, Bioinformatics and Biology Insights Journal, Cancer Informatics Journal.
